Contact
searchSearch
HMP Global

Chronic Myeloid Leukemia

Featured Article

News
CML Treatment Intolerance Increases Time and Economic Burden Among Practice Providers
10/23/2026
Rebecca Amrick
Through interviews with oncology practice managers, researchers estimated the additional time and costs associated with treatment intolerance among patients with chronic myeloid leukemia (CML), identifying key areas for reducing the...
Through interviews with oncology practice managers, researchers estimated the additional time and costs associated with treatment intolerance among patients with chronic myeloid leukemia (CML), identifying key areas for reducing the...
Through interviews with oncology...
10/23/2026
First Report Managed Care
News
Lower Molecular Response Rates Observed Among Underserved Patients With CML
10/20/2026
Rebecca Amrick
Researchers found that patients with chronic myeloid leukemia (CML) from underserved populations had worse outcomes, likely resulting from increased comorbidities and financial barriers, highlighting the need for additional research to...
Researchers found that patients with chronic myeloid leukemia (CML) from underserved populations had worse outcomes, likely resulting from increased comorbidities and financial barriers, highlighting the need for additional research to...
Researchers found that patients...
10/20/2026
First Report Managed Care
News
TKI-Related Adverse Events Negatively Impact Quality of Life Among Patients With CML
10/16/2026
Rebecca Amrick
Researchers found that tyrosine kinase inhibitor (TKI)-related adverse events were associated with decreased quality of life and increased activity impairment among patients with chronic myeloid leukemia (CML).
Researchers found that tyrosine kinase inhibitor (TKI)-related adverse events were associated with decreased quality of life and increased activity impairment among patients with chronic myeloid leukemia (CML).
Researchers found that tyrosine...
10/16/2026
First Report Managed Care
News
Asciminib Associated With Durable Molecular Responses Among Patients With CML-CP
10/09/2026
Rebecca Amrick
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib...
10/09/2026
First Report Managed Care
News
Gene Signature May Help Predict Treatment-Free Remission in CML
09/21/2026
Hannah Musick
A 50-gene transcriptomic signature predicted the likelihood of sustained treatment-free remission after tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia, potentially supporting more individualized treatment...
A 50-gene transcriptomic signature predicted the likelihood of sustained treatment-free remission after tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia, potentially supporting more individualized treatment...
A 50-gene transcriptomic...
09/21/2026
First Report Managed Care
News
Real-World Study Identifies Factors Associated With Successful TKI Discontinuation in CML
09/14/2026
Rebecca Amrick
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who...
09/14/2026
First Report Managed Care
News
The Impact of Asciminib on Patients With Pretreated CML-CP
09/03/2026
Rebecca Amrick
The ASC4OPT study found that asciminib demonstrated comparable efficacy across dosing regimens in patients with pretreated chronic myeloid leukemia in chronic phase (CML-CP), supporting its potential role as a treatment option for patients...
The ASC4OPT study found that asciminib demonstrated comparable efficacy across dosing regimens in patients with pretreated chronic myeloid leukemia in chronic phase (CML-CP), supporting its potential role as a treatment option for patients...
The ASC4OPT study found that...
09/03/2026
First Report Managed Care
News
TKI-Treated CML Survivors Face Long-Term Health and Functional Challenges
08/24/2026
Grace Taylor, MS, MA
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Long-term tyrosine kinase...
08/24/2026
First Report Managed Care
News
Recent CML Advances Reshape Frontline Treatment and TKI Sequencing
08/19/2026
Hannah Musick
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic...
08/19/2026
First Report Managed Care
News
Later-Generation CML Therapies May Have Limited Effect on Patient Out-of-Pocket Costs
08/12/2026
Hannah Musick
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
A new economic analysis suggests...
08/12/2026
First Report Managed Care
News
TKI Dose De-Escalation Preserves Treatment-Free Remission in CML, Study Finds
07/20/2026
Grace Taylor, MS, MA
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine...
07/20/2026
First Report Managed Care

Newsfeed

News
CML Treatment Intolerance Increases Time and Economic Burden Among Practice Providers
10/23/2026
Rebecca Amrick
Through interviews with oncology practice managers, researchers estimated the additional time and costs associated with treatment intolerance among patients with chronic myeloid leukemia (CML), identifying key areas for reducing the...
Through interviews with oncology practice managers, researchers estimated the additional time and costs associated with treatment intolerance among patients with chronic myeloid leukemia (CML), identifying key areas for reducing the...
Through interviews with oncology...
10/23/2026
First Report Managed Care
News
TKI-Related Adverse Events Negatively Impact Quality of Life Among Patients With CML
10/16/2026
Rebecca Amrick
Researchers found that tyrosine kinase inhibitor (TKI)-related adverse events were associated with decreased quality of life and increased activity impairment among patients with chronic myeloid leukemia (CML).
Researchers found that tyrosine kinase inhibitor (TKI)-related adverse events were associated with decreased quality of life and increased activity impairment among patients with chronic myeloid leukemia (CML).
Researchers found that tyrosine...
10/16/2026
First Report Managed Care
News
Asciminib Associated With Durable Molecular Responses Among Patients With CML-CP
10/09/2026
Rebecca Amrick
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib...
10/09/2026
First Report Managed Care
News
Gene Signature May Help Predict Treatment-Free Remission in CML
09/21/2026
Hannah Musick
A 50-gene transcriptomic signature predicted the likelihood of sustained treatment-free remission after tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia, potentially supporting more individualized treatment...
A 50-gene transcriptomic signature predicted the likelihood of sustained treatment-free remission after tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia, potentially supporting more individualized treatment...
A 50-gene transcriptomic...
09/21/2026
First Report Managed Care
News
Real-World Study Identifies Factors Associated With Successful TKI Discontinuation in CML
09/14/2026
Rebecca Amrick
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who...
09/14/2026
First Report Managed Care
News
The Impact of Asciminib on Patients With Pretreated CML-CP
09/03/2026
Rebecca Amrick
The ASC4OPT study found that asciminib demonstrated comparable efficacy across dosing regimens in patients with pretreated chronic myeloid leukemia in chronic phase (CML-CP), supporting its potential role as a treatment option for patients...
The ASC4OPT study found that asciminib demonstrated comparable efficacy across dosing regimens in patients with pretreated chronic myeloid leukemia in chronic phase (CML-CP), supporting its potential role as a treatment option for patients...
The ASC4OPT study found that...
09/03/2026
First Report Managed Care
News
Recent CML Advances Reshape Frontline Treatment and TKI Sequencing
08/19/2026
Hannah Musick
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic...
08/19/2026
First Report Managed Care
News
TKI Dose De-Escalation Preserves Treatment-Free Remission in CML, Study Finds
07/20/2026
Grace Taylor, MS, MA
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine kinase inhibitor (TKI) dose de-escalation preserved treatment-free remission while reducing adverse events in adults with chronic myeloid leukemia (CML).
A study found that tyrosine...
07/20/2026
First Report Managed Care
News
Cavhanza Approved by the FDA to Treat Adults With Ph+ CML
07/20/2026
Rebecca Amrick
Cavhanza (nilotinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), increasing treatment options for CML and possibly improving patient...
Cavhanza (nilotinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), increasing treatment options for CML and possibly improving patient...
Cavhanza (nilotinib) has been...
07/20/2026
First Report Managed Care
News
Review Finds Low Bleeding Risk With Tyrosine Kinase Inhibitor–Anticoagulant Combinations in CML
07/16/2026
Hannah Musick
A systematic review found that combining tyrosine kinase inhibitors with anticoagulants was generally associated with a low incidence of bleeding and thrombotic events in chronic myeloid leukemia, although patients with renal impairment,...
A systematic review found that combining tyrosine kinase inhibitors with anticoagulants was generally associated with a low incidence of bleeding and thrombotic events in chronic myeloid leukemia, although patients with renal impairment,...
A systematic review found that...
07/16/2026
First Report Managed Care
Behind the Bill
DOJ and HHS Launch Health Care False Claims Act Self-Disclosure Pilot Program
10/23/2026
Grace Taylor, MS, MA
The US Department of Justice (DOJ) and Department of Health and Human Services (HHS) have introduced a 6-month pilot program allowing eligible health care organizations to voluntarily disclose potential False Claims Act violations in exchange...
The US Department of Justice (DOJ) and Department of Health and Human Services (HHS) have introduced a 6-month pilot program allowing eligible health care organizations to voluntarily disclose potential False Claims Act violations in exchange...
The US Department of Justice...
10/23/2026
First Report Managed Care
News
CML Treatment Intolerance Increases Time and Economic Burden Among Practice Providers
10/23/2026
Rebecca Amrick
Through interviews with oncology practice managers, researchers estimated the additional time and costs associated with treatment intolerance among patients with chronic myeloid leukemia (CML), identifying key areas for reducing the...
Through interviews with oncology practice managers, researchers estimated the additional time and costs associated with treatment intolerance among patients with chronic myeloid leukemia (CML), identifying key areas for reducing the...
Through interviews with oncology...
10/23/2026
First Report Managed Care
News
ADL-018 Demonstrates Bioequivalence and Comparable Safety to Reference Omalizumab
10/22/2026
Rebecca Amrick
Researchers found that the investigational biosimilar ADL-018 demonstrated pharmacokinetic equivalence and a comparable safety profile to reference omalizumab in healthy participants, supporting its potential as a future therapeutic...
Researchers found that the investigational biosimilar ADL-018 demonstrated pharmacokinetic equivalence and a comparable safety profile to reference omalizumab in healthy participants, supporting its potential as a future therapeutic...
Researchers found that the...
10/22/2026
First Report Managed Care
News
Treatment Switching Associated With Increased Health Care Utilization and Costs Among Patients With AD
10/21/2026
Rebecca Amrick
Researchers found that among patients with moderate to severe atopic dermatitis (AD), those who switched to second-line therapies had higher utilization rates and care costs compared to those who remained on first-line treatments.
Researchers found that among patients with moderate to severe atopic dermatitis (AD), those who switched to second-line therapies had higher utilization rates and care costs compared to those who remained on first-line treatments.
Researchers found that among...
10/21/2026
First Report Managed Care
News
Social Vulnerability Associated With Restrictive PA Policies Among MA Beneficiaries
10/19/2026
Rebecca Amrick
Across Medicare Advantage (MA) plans, researchers found that more socially vulnerable counties had higher rates of prior authorization (PA) and more restrictive policies than less vulnerable counties, illustrating increased disparities among...
Across Medicare Advantage (MA) plans, researchers found that more socially vulnerable counties had higher rates of prior authorization (PA) and more restrictive policies than less vulnerable counties, illustrating increased disparities among...
Across Medicare Advantage (MA)...
10/19/2026
First Report Managed Care
News
Prevalence and Risk Predicators of Secondary Malignancies Among Patients With PV
10/19/2026
Rebecca Amrick
Researchers described the prevalence and incidence of secondary malignancies among adults with polycythemia vera (PV), identifying vulnerable patients with a higher risk of disease transformation and secondary cancers.
Researchers described the prevalence and incidence of secondary malignancies among adults with polycythemia vera (PV), identifying vulnerable patients with a higher risk of disease transformation and secondary cancers.
Researchers described the...
10/19/2026
First Report Managed Care
Behind the Bill
DOJ Streamlines Health Care Fraud Self-Disclosure as Enforcement Priorities Expand
10/16/2026
Grace Taylor, MS, MA
The US Department of Justice’s (DOJ) new health care fraud self-disclosure policy simplifies reporting as broader enforcement priorities put corporate compliance practices in focus.
The US Department of Justice’s (DOJ) new health care fraud self-disclosure policy simplifies reporting as broader enforcement priorities put corporate compliance practices in focus.
The US Department of Justice’s...
10/16/2026
First Report Managed Care
News
TKI-Related Adverse Events Negatively Impact Quality of Life Among Patients With CML
10/16/2026
Rebecca Amrick
Researchers found that tyrosine kinase inhibitor (TKI)-related adverse events were associated with decreased quality of life and increased activity impairment among patients with chronic myeloid leukemia (CML).
Researchers found that tyrosine kinase inhibitor (TKI)-related adverse events were associated with decreased quality of life and increased activity impairment among patients with chronic myeloid leukemia (CML).
Researchers found that tyrosine...
10/16/2026
First Report Managed Care
News
Severe Itch and Skin Lesions Linked to Higher Health Care Costs in Atopic Dermatitis
10/15/2026
Hannah Musick
A real-world US study found that patients with moderate-to-severe atopic dermatitis experiencing both severe itch and severe skin lesions incurred the highest annual health care charges, highlighting the importance of assessing both symptom...
A real-world US study found that patients with moderate-to-severe atopic dermatitis experiencing both severe itch and severe skin lesions incurred the highest annual health care charges, highlighting the importance of assessing both symptom...
A real-world US study found that...
10/15/2026
First Report Managed Care
News
Semaglutide 2.4 mg Shows Favorable Cost-Effectiveness Among Patients With MASH
10/15/2026
Rebecca Amrick
A cost-effectiveness model found semaglutide 2.4 mg to be a clinically beneficial and economically viable treatment option for patients with non-cirrhotic metabolic dysfunction‐associated steatohepatitis (MASH) with moderate to advanced...
A cost-effectiveness model found semaglutide 2.4 mg to be a clinically beneficial and economically viable treatment option for patients with non-cirrhotic metabolic dysfunction‐associated steatohepatitis (MASH) with moderate to advanced...
A cost-effectiveness model found...
10/15/2026
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
What’s Next for Chronic Kidney Disease Treatment and Access
10/22/2026
Roy Moore
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Roy Moore discusses emerging...
10/22/2026
First Report Managed Care
PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care
Pipeline Projections
Examining Newly FDA-Approved Anticoagulants and Upcoming Drugs in the Approval Pipeline
02/12/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline...
02/12/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use